Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
89 employees
Wugen: Advancing immuno-oncology with enhanced, donor-derived cell therapies for various cancers.
HQ
Founded
2018
Wugen, founded with a mission to advance immuno-oncology, is a clinical-stage company specializing in developing off-the-shelf cellular therapies for cancer. The company's core vision is to harness the power of natural killer (NK) cells and chimeric antigen receptor T (CAR-T) cells to create effective treatments for solid tumors, acute myeloid leukemia (AML), and T-cell malignancies. By using enhanced, donor-derived cell therapies, Wugen aims to provide innovative solutions that address significant unmet needs in cancer treatment.
Notable figures affiliated with Wugen include its leadership team and a distinguished Scientific Advisory Board composed of experts in oncology and cell therapy. The company has garnered support from prominent investors committed to advancing cancer therapeutics. Key achievements include the development of their proprietary Memory NK and CAR-T platforms, which have shown promising preclinical results. Wugen's impact lies in its potential to revolutionize cancer treatment through cutting-edge immuno-oncology therapies, offering new hope to patients with challenging malignancies.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Cell Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Wugen founded?
Wugen was founded in 2018.
Where is Wugen's headquarters located?
Wugen's headquarters is located in St. Louis, MO, US.
When was Wugen's last funding round?
Wugen's most recent funding round was for $172M (USD) in July 2021.
How many employees does Wugen have?
Wugen has 89 employees as of Feb 5, 2024.
How much has Wugen raised to-date?
As of July 05, 2023, Wugen has raised a total of $172M (USD) since Jul 15, 2021.
Add Comparison
Total Raised to Date
$172M
USD
Last Update Jul 15, 2021
Last Deal Details
$172M
USD
Jul 15, 2021
Series B
Current Employees
89
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts